TheraCoat is a clinical stage specialty pharmaceutical company providing novel and advanced treatments to address unmet needs in the field of urology.
The company has developed proprietary sustained release, hydrogel-based, depot formulations for improving the efficacy and safety profiles of existing drugs.
TheraCoat sustained release technology enables longer exposure of the urinary tract tissue to medications, as compared to standard intravesical instillations, currently administered for the treatment of urinary tract diseases.
TheraCoat core technology is based on using a proprietary and patented reverse thermal-gelation hydrogels, the TCGel family, having ideal properties for the delivery and retention of medications in the urinary tract.
The company’s lead product is MitoGel™ (sustained release formulation of the chemoterapy agent Mitomycin C) for the management of Upper Tract Urothelial Carcinoma (UTUC), an orphan indication with high clinical unmet needs. Recently, TheraCoat has been granted Orphan Drug Designation from the US FDA for MitoGel™ and will shortly commence a phase III clinical study.
In addition, TheraCoat is developing sustained release formulations of Mitomycin C for intravesical treatments for non-muscle-invasive or superficial bladder cancer (NMIBC), and botulinum toxin A formulations for interstitial cystitis (IC) and overactive bladder (OAB). These treatments together address millions of patients worldwide.
COME MEET US AT:
TheraCoat will be present at EAU, Madrid and meet investigators and companies interested in collaboration.
TheraCoat will exhibit its novel sustained release platform at booth #1351 . Companies interested are welcomed to meet us.
In addition, an investigators meeting on UTUC will be held on May 16th. Investigators interested in joining TheraCoat’s UTUC clinical trial are invited to write to us.